Federal Ruling Keeps Mifepristone Accessible Amid Ongoing Legal Battles
In a significant legal development, a federal judge in Louisiana has temporarily maintained national access to mifepristone, a key medication used in abortions. This decision comes amidst ongoing scrutiny and a broader debate over telehealth abortion services, which have become increasingly prevalent, now constituting over one in four abortions in the U.S.
Judge David C. Joseph’s 37-page ruling granted the FDA’s request to pause the case while the agency reviews the safety of mifepristone, a drug in use for more than 25 years. However, the ruling does not fully endorse the telehealth method, which allows the drug to be prescribed via telemedicine. “Ultimately it is FDA, not this Court, that possesses the expertise to evaluate scientific evidence and make public health judgments,” Joseph noted.
A Republican Divide on Abortion Policies
Legal history professor Mary Ziegler from the University of California, Davis, comments on the internal conflict among Republicans regarding abortion policies. “We’re seeing a kind of civil war between Republicans about how quickly and how far to go that the Louisiana case exemplifies,” Ziegler stated. This case places pressure on both the president and Congress to adopt a more definitive stance on the issue.
For President Trump, the matter is particularly complex. The FDA under his administration, while seeking a pause, appears to be taking a stricter approach towards mifepristone, potentially counteracting measures implemented by the Biden administration to enhance telehealth abortion access. This has led to temporary delays but increased pressure on the FDA to complete its review.
Trump has faced criticism from congressional Republicans, particularly after suggesting flexibility on abortion restrictions. Notably, abortion did not feature in his State of the Union address, reflecting a delicate balance between satisfying his base and appealing to independent voters, many of whom favor abortion rights according to Gallup polls.
Louisiana’s Role in the Legal Challenge
The state of Louisiana is the primary plaintiff in this legal challenge, questioning the FDA’s 2023 decision to permit mifepristone prescriptions via telemedicine. Previously, the drug required an in-person appointment. Louisiana’s complaint argues that this change undermines the Dobbs decision, which overturned Roe v. Wade, by facilitating mail-order access to the medication.
Rosalie Markezich, a Louisiana resident, is also named as a plaintiff. The complaint describes her feeling coerced into taking the FDA-approved abortion drugs ordered by her boyfriend. This case is part of a broader strategy by Louisiana, which has been active in implementing anti-abortion measures, including criminal charges against out-of-state telemedicine providers and reclassifying mifepristone as a controlled substance.
Continued Access and Abortion Rates
Despite the legal battles and state bans, abortion rates in the U.S. have remained consistent. Research indicates that countries with strict abortion laws have similar abortion rates to those without such restrictions, suggesting that legal limitations do not prevent abortions but may complicate access.
The Guttmacher Institute reports that there were approximately 1.1 million abortions in the U.S. in 2025, with about 2,500 occurring in Louisiana. Even in states with abortion bans, telehealth abortions were accessed by around 91,000 patients last year.
For individuals like E., a resident of New Orleans, the ability to access abortion medications via mail has been crucial. E. expressed relief at having the option, despite living in a state with strict abortion laws, underscoring the ongoing importance of telehealth services in the reproductive rights landscape.
